Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

HLA-B gene somatic insertion/deletion mutations in patients with acute myelogenous leukaemia

N. Königova, I. Skoumalova, J. Onderkova, Z. Ambruzova, T. Szotkowski, Z. Koristek, A. Maluskova, L. Raida, F. Mrazek,

. 2018 ; 45 (6) : 323-328. [pub] 20180727

Language English Country England, Great Britain

Document type Case Reports, Journal Article

Loss of heterozygosity is considered to be the most common type of tumour-specific somatic mutation of the human leucocyte antigens (HLA) genes in patients with haematological malignancies. Nevertheless, subtle DNA sequence changes, namely short insertions/deletions, may also abolish the expression of HLA molecules and interfere with routine HLA typing. Two male patients with acute myelogenous leukaemia (AML) were indicated for the search of a suitable donor for allogeneic haematopoietic stem cell transplantation (aHSCT). The patients and their relatives were initially HLA typed by serological and DNA techniques at a low-resolution level. The HLA high-resolution (HR) type was obtained by means of sequencing-based typing (SBT). In both cases, anomalous frameshifts in the sequence were observed in the HLA-B gene, namely in exon 3 (Case 1, heterozygous deletion of two bases) and exon 4 (Case 2, heterozygous insertion of two bases). In the second case, the insertion variant was associated with a loss of HLA-B8 expression. To reveal whether these sequence patterns may be caused by somatic mutations in the malignant cells, blood sample in remission (Case 1) and buccal swab sample (Case 2) were collected from the patients. In an important manner, the SBT in these germline samples revealed common HLA-B*07:02,*15:01 (Case 1) and HLA-B*08:01,*35:02 (Case 2) types with no evidence for the sequence alteration observed in the initial samples. In conclusion, the insertion/deletion sequence variants of the HLA-B gene in two patients were limited to the initial blood samples with a substantial proportion of AML cells and thus may be attributed to the somatic mutation in the malignant cells. HLA somatic mutations should be taken into account in patients with haematological malignancies to prevent HLA mistyping and inappropriate selection of an aHSCT donor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012521
003      
CZ-PrNML
005      
20190412094816.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/iji.12393 $2 doi
035    __
$a (PubMed)30051604
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Königova, Nikola $u Department of Immunology, University Hospital, Olomouc, Czech Republic. Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
245    10
$a HLA-B gene somatic insertion/deletion mutations in patients with acute myelogenous leukaemia / $c N. Königova, I. Skoumalova, J. Onderkova, Z. Ambruzova, T. Szotkowski, Z. Koristek, A. Maluskova, L. Raida, F. Mrazek,
520    9_
$a Loss of heterozygosity is considered to be the most common type of tumour-specific somatic mutation of the human leucocyte antigens (HLA) genes in patients with haematological malignancies. Nevertheless, subtle DNA sequence changes, namely short insertions/deletions, may also abolish the expression of HLA molecules and interfere with routine HLA typing. Two male patients with acute myelogenous leukaemia (AML) were indicated for the search of a suitable donor for allogeneic haematopoietic stem cell transplantation (aHSCT). The patients and their relatives were initially HLA typed by serological and DNA techniques at a low-resolution level. The HLA high-resolution (HR) type was obtained by means of sequencing-based typing (SBT). In both cases, anomalous frameshifts in the sequence were observed in the HLA-B gene, namely in exon 3 (Case 1, heterozygous deletion of two bases) and exon 4 (Case 2, heterozygous insertion of two bases). In the second case, the insertion variant was associated with a loss of HLA-B8 expression. To reveal whether these sequence patterns may be caused by somatic mutations in the malignant cells, blood sample in remission (Case 1) and buccal swab sample (Case 2) were collected from the patients. In an important manner, the SBT in these germline samples revealed common HLA-B*07:02,*15:01 (Case 1) and HLA-B*08:01,*35:02 (Case 2) types with no evidence for the sequence alteration observed in the initial samples. In conclusion, the insertion/deletion sequence variants of the HLA-B gene in two patients were limited to the initial blood samples with a substantial proportion of AML cells and thus may be attributed to the somatic mutation in the malignant cells. HLA somatic mutations should be taken into account in patients with haematological malignancies to prevent HLA mistyping and inappropriate selection of an aHSCT donor.
650    _2
$a HLA-B7 antigen $x genetika $7 D015793
650    _2
$a HLA-B8 antigen $x genetika $7 D015795
650    _2
$a lidé $7 D006801
650    12
$a mutace INDEL $7 D054643
650    _2
$a akutní myeloidní leukemie $x genetika $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x genetika $7 D009363
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skoumalova, Ivana $u Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Department of Haemato-oncology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Onderkova, Jana $u Department of Immunology, University Hospital, Olomouc, Czech Republic. Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Ambruzova, Zuzana $u Department of Immunology, University Hospital, Olomouc, Czech Republic. Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Szotkowski, Tomas $u Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Department of Haemato-oncology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Koristek, Zdenek $u Department of Haemato-oncology, University Hospital, Ostrava, Czech Republic. Medical Faculty, Ostrava University, Ostrava, Czech Republic.
700    1_
$a Maluskova, Alena $u Blood Centre, University Hospital, Ostrava, Czech Republic.
700    1_
$a Raida, Ludek $u Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Department of Haemato-oncology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Mrazek, Frantisek $u Department of Immunology, University Hospital, Olomouc, Czech Republic. Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
773    0_
$w MED00008484 $t International journal of immunogenetics $x 1744-313X $g Roč. 45, č. 6 (2018), s. 323-328
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30051604 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412094834 $b ABA008
999    __
$a ok $b bmc $g 1391831 $s 1050826
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 45 $c 6 $d 323-328 $e 20180727 $i 1744-313X $m International journal of immunogenetics $n Int J Immunogen $x MED00008484
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...